Innovating.works Conecta tu I+D

Showing 1 to 20 of 50 results

SYNTHIA: Synthetic Data Generation Framework for Integrated Validation of Use Cases and AI Healthcare Applica... SYNTHIA is an ambitious collaboration between public and private institutions to facilitate the responsible use of Synthetic Data (SD) in he...
2024-08-09 - 2029-08-31 | Financiado

e-QuoL: e health tools to promote Equality in Quality of Life for childhood to young adulthood cancer patien... HUSYHTYMA participó en un HORIZON EUROPE: HORIZON-MISS-2023-CANCER-01 Cancer affects 35,000 children, adolescents and young adults (CAYAC) in Europe each year. Current 5-year survival rates are 80%, but the int...
2023-12-13 - 2027-12-31 | Financiado

PALLIAKID: COMPREHENSIVE PAEDIATRIC PALLIATIVE CARE APPROACH HUSYHTYMA participó en un HORIZON EUROPE: HORIZON-HLTH-2023-DISEASE-03 PALLIAKID is an interdisciplinary project aiming to evaluate the feasibility, effectiveness, and cost-effectiveness of novel interventions f...
2023-12-11 - 2028-05-31 | Financiado

QUANTUM: Quality Utility and Maturity Measured Developing a Data Quality and Utility Label for HealthData@E... HUSYHTYMA participó en un HORIZON EUROPE: HORIZON-HLTH-2023-TOOL-05 Context: Data users (i.e., researchers, innovators, regulation agencies and policy-makers) need high-quality data. In HealthData@EU, data ho...
2023-12-11 - 2026-06-30 | Financiado

PHEMS: Pediatric Hospitals as European drivers for multi-party computation and synthetic data generation ca... HUSYHTYMA tramitó un HORIZON EUROPE: HORIZON-HLTH-2022-IND-13 Cross-border collaboration can tackle the challenges in accessing relevant health data essential for international collaboration between sci...
2023-10-09 - 2026-09-30 | Financiado

IMPORTANT: IMPlementing geriatric assessment for dose Optimization of CDK 4/6-inhibitors in older bReasT cAncer... HUSYHTYMA participó en un HORIZON EUROPE: HORIZON-MISS-2022-CANCER-01 Current evidence from both randomized trials and real-world evidence studies suggests that older breast cancer patients derive clinical bene...
2023-04-24 - 2028-04-30 | Financiado

ENDOTARGET: Systemic Endotoxemia as the driver of chronic inflammation - Biomarkers and novel therapeutic target... HUSYHTYMA tramitó un HORIZON EUROPE: HORIZON-HLTH-2022-STAYHLTH-02 Rheumatic diseases (RDs) affect more than 40% of Europe's population and cause significant disability, pain, reduced lifespan and a very hig...
2023-01-01 - 2026-12-31 | Financiado

i4KIDS-EUROPE: Inclusive and Interconnected Ecosystem to Boost Paediatric Innovation in Europe-i4KIDS-EUROPE HUSYHTYMA participó en un HORIZON EUROPE: HORIZON-EIE-2022-CONNECT-01 Innovation in paediatric health is critical to ensure that children, regardless of their age, health condition, socio-economic situation or...
2022-12-16 - 2025-01-14 | Financiado

ONCOVALUE: Implementing value-based oncology care at European cancer hospitals: An AI-based framework for asses... HUSYHTYMA tramitó un HORIZON EUROPE: HORIZON-HLTH-2022-TOOL-11 ONCOVALUE will unlock the full potential of real world data (RWD) collected in European cancer hospitals and institutes to ease the decision...
2022-12-01 - 2026-11-30 | Financiado

ENDOTARGET: Systemic Endotoxemia as the driver of chronic inflammation - Biomarkers and novel therapeutic target... HUSYHTYMA tramitó un HORIZON EUROPE: HORIZON-HLTH-2022-STAYHLTH-02 Rheumatic diseases (RDs) affect more than 40% of Europe's population and cause significant disability, pain, reduced lifespan and a very hig...
2022-11-15 - 2026-12-31 | Financiado

Long Covid: Decision support for prediction and management of Long Covid Syndrome (LCS) HUSYHTYMA tramitó un HORIZON EUROPE: HORIZON-HLTH-2021-DISEASE-04 We will develop tools and knowledge to support physicians in accurately managing Long COVID syndrome (LCS) which has a significant impact on...
2022-05-23 - 2026-05-31 | Financiado

DECIDER: Improved clinical decisions via integrating multiple data levels to overcome chemotherapy resistance... HUSYHTYMA participó en un H2020: H2020-SC1-BHC-2018-2020 The goals of this inter-disciplinary project are to 1) gain understanding of the mechanisms causing chemoresistance in high-grade serous ova...
2021-01-21 - 2026-07-31 | Financiado

AI-Mind: Intelligent digital tools for screening of brain connectivity and dementia risk estimation in people... More than 10 million Europeans show signs of mild cognitive impairment (MCI), a condition intermediate between normal brain ageing and demen...
2021-01-18 - 2026-02-28 | Financiado

AICCELERATE: AI Accelerator A Smart Hospital Care Pathway Engine HUSYHTYMA tramitó un H2020: H2020-DT-2018-2020 Healthcare systems lack flexible AI solutions that allow hospitals to improve efficiency and the quality of patient care. Current solutions...
2020-12-15 - 2024-04-30 | Financiado

INTERVENE: International consortium for integrative genomics prediction HUSYHTYMA participó en un H2020: H2020-SC1-FA-DTS-2018-2020 The aim of INTERVENE is to develop and test next generation tools for disease prevention, diagnosis, and personalised treatment utilizing th...
2020-12-07 - 2025-12-31 | Financiado

BIGPICTURE: Central Repository for Digital Pathology HUSYHTYMA participó en un H2020: H2020-JTI-IMI2-2019-18-two-stage BIGPICTURE, a pathology-led consortium, has the vision to become the catalyst in digital transformation in Pathology. Our mission is to crea...
2020-11-26 - 2027-01-31 | Financiado